Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature

  • C. Venturin1,
  • S. Nancey1, 2,
  • P. Danion1,
  • M. Uzzan3,
  • M. Chauvenet1,
  • C. Bergoin1,
  • X. Roblin4,
  • B. Flourié1, 2 and
  • G. Boschetti1, 2, 5Email author
BMC GastroenterologyBMC series – open, inclusive and trusted201717:80

https://doi.org/10.1186/s12876-017-0633-6

Received: 24 January 2017

Accepted: 5 June 2017

Published: 19 June 2017

Abstract

Background

Ustekinumab is a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 which is involved in the pathogenesis of several inflammatory diseases. Ustekinumab is approved for psoriasis and psoriatic arthritis treatment and has been successfully evaluated in phase II and III trials for patients with Crohn’s disease (CD).

Case presentation

We report here the case of a patient who became pregnant during treatment with ustekinumab for a refractory CD and which ended in miscarriage.

Conclusion

Ustekinumab is a relatively new pharmacotherapy and in addition to this clinical case, we reviewed the published literature concerning the use of this treatment during pregnancy and its consequences on pregnancy and fetus outcome.

Keywords

Anti-IL12/23 Ustekinumab Crohn’s disease Pregnancy

Background

Ustekinumab, a fully human IgG1-κ monoclonal antibody directed against the p40 subunit shared by IL-12 and IL-23, inhibits the action of these 2 cytokines, which are critically involved in the pathogenesis of Crohn’s disease (CD). This novel biologic agent is currently approved in psoriasis and represents also a promising agent for the treatment of CD according to the efficacy and safety profile from recent pivotal phase II and III trials [1]. In addition, the efficacy of ustekinumab in CD has been reported in 3 different real-life retrospective studies [24]. Ustekinumab has been recently approved in France for a temporary recommendation of use in moderate to severe active CD with previous biologic therapy anti-TNF and anti-α4β7 integrin (vedolizumab) failures. As most of the female CD patients susceptible to require ustekinumab are of childbearing age and because ustekinumab is a relatively novel agent, its consequences on pregnancy and fetus outcome are a critical concern. Currently, available data regarding this issue – which mainly come from patients treated for psoriasis – remain scarce in the context of CD. We report here the case of a 32 year-old patient who became unexpectedly pregnant during treatment with ustekinumab for a refractory CD and ultimately had a miscarriage.

Case presentation

We here report on a 32-year-old Caucasian female followed in our institution for a severe ileocolonic refractory CD since 2007 who had failed to respond to various therapies, including thiopurines, anti-TNF (infliximab and adalimumab) and to vedolizumab. Her obstetrical history included four pregnancies, one of which has ended by a miscarriage before 20 weeks and the 3 others were normal with 3 healthy children (gravidity 4 and parity 3, G4P3). Given severe flares of CD featured by abdominal cramping, chronic diarrhea, body weight loss despite oral steroids, ustekinumab was started in January 2016 (induction with subcutaneous (s.c.) injection of ustekinumab 90 mg at week 0, 2, 4) followed by a maintenance regimen with s.c. injections every 8 weeks. This led to a rapid clinical improvement and she quickly achieved a complete clinical and biological remission. In June 2016, after her 5th injection, she reported an unintended pregnancy. The last dose of ustekinumab had been administered at week 4 of gestation. Ultrasound (US) examination confirmed this inadvertent pregnancy and ustekinumab therapy was subsequently discontinued due to the lack of clinical data supporting this medication’s use during pregnancy. A systematic folic acid supplementation (1 mg/day) was started immediately according to French recommendations. In July 2016, while the patient was still in remission, a second US exam was performed and reported in utero fetal death (dating from week 4, close to the last ustekinumab injection) and ultimately leading to a miscarriage at 8 weeks of gestation.

Discussion and conclusions

Up to now, the outcomes of inadvertent pregnancies occurring during ustekinumab therapy have been registered in only 65 cases of patients (most of them treated for psoriasis and only 3 for CD) [512]. All published cases are summarized in Table 1. Regarding the 3 cases of maternal exposures to ustekinumab during pregnancy that occurred in CD, 2 patients had also paradoxical psoriaform skin reactions and were treated with doses of ustekinumab, according to the indication for psoriasis (e.g. 45 mg s.c. every 12 weeks). In the present case, ustekinumab doses were higher both during induction and maintenance regimens (270 mg the first month followed by 90 mg every 8 weeks), as usually used in active refractory CD. Among all the published cases or unpublished data from clinical studies, spontaneous abortion was reported in 6 cases (9%), 16 cases of live births with no adverse event or congenital abnormality or birth defect, one case of live birth with premature baby with atrioventricular septal defect and right aortic arch and 2 cases of live birth associated with neonatal jaundice were reported. Among the 30 other cases out of the 65, in whom maternal exposure to ustekinumab during pregnancy was recorded, the pregnancy outcomes were unknown and finally in 10 cases, an elective termination of the pregnancy was performed. Ages of the pregnant women and additional risk factors of miscarriage as well as the duration of ustekinumab therapy during pregnancy were variable among the cases. In the present case, the patient was at increased risk of miscarriage since she had already experienced an obstetrical history of miscarriage in the past in the absence of ustekinumab exposure and given her age. As for psoriasis, CD raises by itself the risk of miscarriage especially during flare-ups of the disease [13].
Table 1

Pregnancy outcomes in ustekinumab-treated patients

Indication

Age

(years old)

Outcome of pregnancy

Reference in the article

Pustular psoriasis and psoriatic arthritis

22

Uneventful

5

Psoriasis

35

Miscarriage

(at 12 weeks of gestation)

6

Psoriasis

34

Uneventful

7

Psoriasis

24

Uneventful

7

Psoriasis

21

Uneventful

8

Psoriasis

25

Uneventful

9

Psoriasis

22

Uneventful

10

Psoriasis

29

Uneventful

10

Psoriasis

33

Unknown

10

Paradoxical psoriasis and Crohn’s disease

28

Uneventful

11

Crohn’s disease

37

Uneventful

12

Crohn’s disease

32

Miscarriage

(at 8 weeks of gestation)

This report

Ustekinumab is an IgG1 monoclonal antibody that cannot cross the placenta by simple diffusion, but in contrast its active transport is mediated by the fetal Fc receptors expressed in the placenta. The expression of such Fc receptors is detected after 14 weeks of gestation and therefore the active transport of the biologic agent begins from the second trimester and increases rapidly till the end of pregnancy [14]. Interestingly, animal studies in pregnant monkeys, using high dose of ustekinumab, failed to demonstrate an enhanced risk for the foetus. Additionally no adverse event on pregnant females or foetuses have been noticed and the abortion rates were similar both in animals exposed to the drug compared to those without exposure [15, 16]. Ustekinumab has been subsequently classified as Pregnancy FDA category B, which means that there is no risk reported from animal studies; however, there are, up to date, no adequate and dedicated studies in women receiving ustekinumab during pregnancy. Interleukins 12 and 23 are implicated in the pathophysiology of CD but also have been involved in uterine physiology since they have been related to the impaired implantation of an embryo and subsequently development of the trophoblast [17]. These pro-inflammatory cytokines are specifically blocked by ustekinumab which may, at least theoretically, impact pregnancy by this way.

Collectively, all these data do not allow drawing final conclusions on the safety or the potential teratogenicity of ustekinumab in pregnancy due to the too small number of reported cases as well as their heterogeneity and given that spontaneous abortions often occur without knowledge of pregnancy. Gastroenterologists are faced with questions about the safety of this novel biologic agent during gestation. Teratogenic and abortion risks must be balanced with the risk of uncontrolled gut inflammation and complications in refractory CD. Even if animal studies using high doses of ustekinumab did not report teratogenicity and even if the risk of fetal drug-exposure may be outweighed by the clinical benefit for the mother, the uncertainty regarding potential risks should led the physician to avoid the use of ustekinumab in pregnant CD patients. Large registries and prospective dedicated studies are warranted in the future to definitively conclude.

Abbreviations

CD: 

Crohn’s disease

S.c.: 

Subcutaneous

US: 

Ultrasound

Declarations

Acknowledgements

Not applicable.

Funding

No funding for this work.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions

CV and SN: acquisition of data, drafting of the manuscript. PD: acquisition of data and critical revision of the manuscript for important intellectual content. MU, MC and CB: critical revision of the manuscript for important intellectual content. XR, BF, SN and GB: study concept and design, drafting of the manuscript and study supervision. All authors read and approved the final manuscript.

Competing interests

None for CV, PD, MU, MC, CB. SN has received consulting fees from Merck, AbbVie, Takeda, Ferring, Norgine, Vifor Pharma, Novartis, Janssen, Hospira, Novartis, Tillots Pharma, Boehringer Ingelheim, and HAC-Pharma. XR, BF and GB have received consulting fees from AbbVie, MSD, Janssen Cilag, and Takeda.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the editor of this journal.

Ethics approval and consent to participate

A consent to participate was obtain from the participant to report individual patient data. Not applicable (case report).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gastroenterology, Lyon-Sud hospital, Hospices Civils de Lyon, Université Lyon1
(2)
INSERM U1111, Centre International de Recherche en Infectiologie
(3)
Department of Gastroenterology and Nutritional Support, Beaujon Hospital, Assistance Publique des Hôpitaux de Paris, Université Paris VII
(4)
Department of Gastroenterology, Saint-Etienne hospital
(5)
Service d’Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud

References

  1. Khanna R, Preiss JC, MacDonald JK, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;5:CD007572.Google Scholar
  2. Kopylov G, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8:1516–22.View ArticlePubMedGoogle Scholar
  3. Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–50.View ArticlePubMedGoogle Scholar
  4. Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–9.View ArticlePubMedGoogle Scholar
  5. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240–1.PubMedGoogle Scholar
  6. Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6:105–7.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol. 2014;55:235–6.View ArticlePubMedGoogle Scholar
  8. Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30:488–90.View ArticlePubMedGoogle Scholar
  9. Rocha K, Piccinin MC, Kalache LF, et al. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology. 2015;231:103–4.View ArticlePubMedGoogle Scholar
  10. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther. 2017; doi:https://doi.org/10.1111/dth.12454.
  11. Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;11. http://www.google.fr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&sqi=2&ved=0ahUKEwidz9fJ2dDNAhVpDJoKHZ9vA4wQFggoMAI&url=http%3A%2F%2Fmc.manuscriptcentral.com%2Fjeadv&usg=AFQjCNG27uH58v-l18iH8wc8wPKGAGggpg&sig2=b6zBRbH4k3qAtl51_FF_BQ&bvm=bv.125801520,d.bGs. doi: https://doi.org/10.1111/jdv.13499.
  12. Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–6.View ArticlePubMedGoogle Scholar
  13. Stephansson O, Larsson H, Pedersen L, et al. Crohn’s disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509–15.View ArticlePubMedGoogle Scholar
  14. Kane SV, Acquah LA. Placenta transport of immunoglobulins : a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228–33.View ArticlePubMedGoogle Scholar
  15. Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23 p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–63.View ArticlePubMedGoogle Scholar
  16. Enright B, Tornesi B, Weinbauer G, et al. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody. Birth Defects Res B Dev Reprod Toxicol. 2012;95:431–43.View ArticlePubMedGoogle Scholar
  17. Lédée-Bataille N, Dubanchet S, Coulomb-L’Hermine A, et al. A new role for natural killer cells, interleukine 12 and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril. 2004;81:59–65.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement